Classical cannabis dosing follows the intuitive assumption of "more active compound = more effect." This linearity is, in neuropharmacological terms, simply wrong. What many consumers don't know: The endocannabinoid system (ECS) behaves biphasically, meaning low and high doses of the very same compound can trigger opposite effects. This phenomenon is not anecdotal – it is documented in dozens of peer-reviewed studies (e.g., Bhattacharyya et al., 2015; Zuardi, 1984; Zuardi & Karniol, 1983) and forms the neurobiological foundation of microdosing.

The Endocannabinoid System: CB1 and CB2 Receptors

The ECS is the human body's most important neuromodulatory regulation system. It consists of two core components:

• CB1 receptors (G_i/o-coupled G-protein-coupled receptors): Primarily located in the central nervous system (brain) – especially in the hippocampus (memory), the amygdala (emotion/anxiety), the prefrontal cortex (executive functions), the striatum (reward/motivation) and the hypothalamus (appetite, temperature regulation). This is where the psychoactive effects of THC originate.
• CB2 receptors: Expressed predominantly in the peripheral nervous system, the immune system (spleen, lymph nodes, macrophages) and the gastrointestinal tract. They mediate anti-inflammatory, immunomodulatory and neuroprotective effects without any psychoactive component.

Both receptor types are occupied by the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Phytocannabinoids such as Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) interact with this system in different ways: THC is a partial agonist at CB1 and CB2 with roughly 50 % of the intrinsic activity of a full agonist, whereas CBD acts primarily as an allosteric modulator and as a reuptake inhibitor of the anandamide transporter (FAT/ABHD6/ABHD12).

Receptor Downregulation vs. Sensitization

Chronic high-dose consumption (regularly > 0.2–0.5 g THC-equivalent doses) induces homologous desensitization followed by downregulation of CB1 receptors:

• Desensitization: The receptors are phosphorylated through sustained agonist binding (GRK/β-arrestin pathway), which uncouples the G-protein and blocks signal transduction. PET studies (Hirvonen et al., 2012) show that after 28 days of abstinence, CB1 receptor density and affinity are almost completely reversible.
• Downregulation: Under continuous stimulation, receptor density is reduced via internalization (endocytosis into clathrin-coated pits) and lysosomal degradation. The result: tolerance. The same dose delivers less effect and the consumer escalates – a classic dose-escalation cycle.

Microdosing reverses this process: By keeping CB1 receptor stimulation at sub-threshold to minimally effective levels, no desensitization pressure builds up. Instead, user reports and clinical observations point to re-sensitization – meaning CB1 receptor density remains stable or recovers, while the therapeutic effect profile is preserved. In the literature, this phenomenon is described as "receptor resensitization" or the maintenance of "basal-level receptor saturation."

The Biphasic Dose–Response Curve

The biphasic nature of THC is the central argument for microdosing. In simplified form:

The cause lies in the differential recruitment of neural networks: Low THC concentrations primarily activate CB1 receptors on GABAergic interneurons in the prefrontal cortex and ventral tegmental area (VTA), which subtly modulates dopamine release in the nucleus accumbens – the "reward and focus effect." As THC levels rise, CB1 receptors in limbic structures (amygdala, hippocampus) are increasingly stimulated, activating the anxiogenic and cognition-disrupting component.

Terpene Synergy in the Low-Dose Range

In microdosing, the terpene profile plays a disproportionately large role, because even low cannabinoid concentrations are significantly modulated through the so-called entourage effect (Mechoulam & Ben-Shabat, 1998). The following terpenes are especially effective within the therapeutic window:

Terpene	Pharmacological Effect	Vaporization Point
β-Myrcene	Muscle-relaxing, sedating (at high doses), synergistic with THC at 155 °C	167 °C
d-Limonene	Anxiolytic, mood-elevating, gastroprotective	176 °C
α-Pinene	Bronchodilator, acetylcholinesterase inhibitor (counters brain fog)	155 °C
β-Caryophyllene	Selective CB2 agonist, anti-inflammatory, analgesic	169 °C
Linalool	Sedating, GABAergic modulating, anxiolytic	198 °C

The key point: In the low-dose range the terpenes are preserved, without the cannabinoid load overwhelming sensory perception. During high-dose vaporization (temperatures > 210 °C, full chamber), the psychoactive cannabinoids dominate the effect profile, while the fine-tuning of the terpenes is lost to sensory overload.

Why a half-filled vaporizer doesn't merely "deliver less" but works proportionally worse can be explained in purely physical terms. Every herb chamber is a porous bed ("packed bed") through which hot air flows and transfers heat energy to the plant matrix. The efficiency of this energy transfer is governed by several parameters.

The Problem of Oversized Chambers (0.3–0.5 g)

Standard herb chambers in most vaporizers have a usable volume of 0.3–0.5 g. If such a chamber is only half filled, three physical problems arise:

1. Incomplete Convection: In a half-filled chamber, a large air pocket forms above the herb bed. The hot air takes the path of least resistance through this air pocket and partly flows around the actual herb mass instead of penetrating it. The resulting extraction is inhomogeneous.
2. Channeling (Airflow Channeling): If the herb bed is unevenly compacted, the hot air forms preferred channels – comparable to "channeling" during espresso extraction. Herbs in the flow channels are overheated and over-extracted, while herbs in the edge areas remain virtually untouched. The result: losses of up to 30–40 % of the potential active-compound yield.
3. Thermal Decomposition from Residual Heat: Conduction and hybrid systems (PAX Plus, Crafty+, Mighty+) actively heat the chamber. After the session, residual heat remains that raises the unused herbs in the edge areas beyond the actual vaporization temperature. These herbs then decompose thermally (forming benzene, traces of formaldehyde and other pyrolysis products) and are useless for the next session.

Microdosing: Higher Active-Compound Yield per Milligram

With a microdose of 0.05–0.1 g in a correspondingly sized or reduced chamber, you get fundamentally different heat management:

• Low Layer Thickness (< 2 mm): The hot air penetrates the entire herb volume homogeneously. There is no noteworthy temperature gradient between the top and bottom of the herb bed – all plant cells reach the vaporization temperature almost simultaneously.
• Instant Vaporization: The distillation dynamics shift from prolonged convection extraction (30–60 seconds of heating time for full chambers) to near-instantaneous active-compound release (3–10 seconds). This reduces thermal stress on the terpenes and enables precise temperature control.
• No Residual-Heat Bias: The entire quantity of active compound vaporizes in the first session – no "burning in the oven" residual-heat issues, no lost active compounds through incomplete convection.

Reducing Chambers, Dosing Capsules & Chamber Reducers

The technical implementation of microdosing relies on three mechanisms:

1. Dosing Capsules: Aluminum or stainless-steel capsules with a ~0.1 g volume that are inserted into the standard, larger chamber. The metal shell conducts heat to the herbs, while the remaining chamber size continues to utilize convection in the edge areas. Storz & Bickel is the market leader here (compatible with CRAFTY+, MIGHTY+, VENTY). Capsule magazines for on-the-go use significantly improve logistical efficiency.
2. Chamber Reducer / Filling Chamber Reducer: Physical inserts that reduce the usable chamber volume. Storz & Bickel offers an official filling chamber reducer. On DynaVap vaporizers, the "Adjust-a-Bowl" function of the M7 takes on this task.
3. Native Small Chambers: Some vaporizers are dimensioned for small quantities right out of the box (Firefly 2+ with ~0.15 g, Tinymight 2 with ~0.05–0.1 g in on-demand mode, desktop ball vapes with 0.05 g bowl adapters).

Not every vaporizer is equally well suited for microdosing. The selection depends on chamber geometry, heating method,